Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect a new version of a clinical trial for Classical Hodgkin Lymphoma, with significant changes in the treatment regimen and the removal of detailed descriptions of previous treatments. The principal investigator's name has been retained, but the previous version's extensive content on treatment protocols has been largely deleted.SummaryDifference39%
- Check16 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed the date 2025-03-25 while adding the dates 2025-01-09 and 2024-12-31.SummaryDifference0.8%
- Check24 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check74 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check81 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.